Evaluating the effect of Cabergoline on controlling blood glucose in type 2 diabetics under treatment with Metformin

Abstract

The aim of this study was to determine the effect of Cabergoline add on metformin on glycemic control of patients with type 2 diabetes mellitus (DM). Methods and Materials: This was a double blind clinical trial, in all selected subjects we performed a general physical examination; blood pressure (systolic and diastolic), height and weight measurement. Initial laboratory parameters of fasting plasma glucose (FBG), 2 hours postprandial plasma glucose (2HPPG), HbA1c, total cholesterol (T-Chol), triglycerides (TG), high density lipoproteins (HDL), liver and renal function tests, and a B-HCG (in women of reproductive age) were obtained. The subjects included in the study were randomly assigned into two case and control groups, the intervention group received 0.25 mg weekly Cabergoline tablets (Caberlin® Iran Hormone Company) for first 2 weeks and 0.5 mg per week for next 12 weeks. Control group received placebo tablets (similar to Cabergoline tablets in shape and package). All clinical and laboratory studies repeated 3 months after initial visit. During the study period, patients advised that do not change their diet and physical activity. Results: HbA1c, TG and 2HPPG levels were significantly improved after intervention in the case group, while FBS, T-CHO, LDL and HDL levels were not significantly different between the two groups after the intervention.